Theriva Biologics Files 8-K: Name Changes & Financials

Ticker: TOVX · Form: 8-K · Filed: Apr 16, 2024 · CIK: 894158

Theriva Biologics, Inc. 8-K Filing Summary
FieldDetail
CompanyTheriva Biologics, Inc. (TOVX)
Form Type8-K
Filed DateApr 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-actions, filing-update

TL;DR

Theriva Biologics (formerly Synthetic Biologics) filed an 8-K with financial updates and historical name changes.

AI Summary

On April 16, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., Adeona Pharmaceuticals, Inc., and Pipex Pharmaceuticals, Inc., with name changes occurring on March 5, 2012, October 27, 2008, and December 14, 2006, respectively. The company is incorporated in Nevada and its fiscal year ends on December 31.

Why It Matters

This filing provides an update on Theriva Biologics' corporate history, including previous names, which can be important for understanding its lineage and potential liabilities or assets. It also signals the submission of financial statements and exhibits.

Risk Assessment

Risk Level: low — This filing is primarily administrative and informational, detailing past company names and the submission of standard reports, posing no immediate new risks.

Key Players & Entities

  • Theriva Biologics, Inc. (company) — Registrant
  • Synthetic Biologics, Inc. (company) — Former company name
  • Adeona Pharmaceuticals, Inc. (company) — Former company name
  • Pipex Pharmaceuticals, Inc. (company) — Former company name
  • April 16, 2024 (date) — Date of report
  • March 5, 2012 (date) — Date of name change
  • October 27, 2008 (date) — Date of name change
  • December 14, 2006 (date) — Date of name change

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What were the previous names of Theriva Biologics, Inc.?

Theriva Biologics, Inc. was formerly known as Synthetic Biologics, Inc., Adeona Pharmaceuticals, Inc., and Pipex Pharmaceuticals, Inc.

When did the company last change its name from Synthetic Biologics, Inc.?

The company changed its name from Synthetic Biologics, Inc. on March 5, 2012.

In which state is Theriva Biologics, Inc. incorporated?

Theriva Biologics, Inc. is incorporated in Nevada.

What is the company's fiscal year end?

The company's fiscal year ends on December 31.

Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-04-16 08:00:24

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica

Filing Documents

01

Item 7.01. Regulation FD Disclosure. Theriva Biologics, Inc. (the "Company") will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the Company presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the Company presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company's Company presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Presentation of Theriva Biologics, Inc., dated April 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 16, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.